The US Food and Drug Administration (FDA) today approved a new autoinjection option for adalimumab-adbm (Cyltezo), a biosimilar to AbbVie's adalimumab (Humira), ahead of Cyltezo's commercial launch on ...
Another Humira biosimilar is here in Boehringer Ingelheim’s Cyltezo. Among the swarm of copycats, BI’s offering stands out because of its interchangeability tag, allowing it to be directly substituted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results